Signaling Mediates Chemotherapy-Induced Cancer Cell Stemness in Gastric Cancer

Overview

Journal Front Pharmacol

Date 2022 May 23

PMID 35600882

Authors

Xue Xiang

Hai-Zhong Ma

Ya-Qiong Chen

Dong-Zhi Zhang

Shi-Xu Ma

Hong-Jing Wang

De-Ming Liu

Yuan Yuan

Hui Cai

Affiliations

Soon will be listed here.

Abstract

Chemotherapy serves as the first choice in clinic to treat advanced gastric cancer. However, emerging evidence indicated the induction of drug resistance and cancer stem cells occasionally by chemotherapy, which seriously limit the therapeutic effects, but the regulatory mechanism remains unclear. Here we treated two human gastric cancer cell lines SGC7901 and BGC823 with 5-Fluorouracil (5-Fu) or Cisplatin (DDP) . The survived cells showed significant increase of drug resistance, cell stemness and cytokine expression and secretion. As such, was applied to stimulate gastric cancer cells, followed by the subpopulation of CSC analysis, sphere formation assay and stemness genes expression analysis. As a result, CSCs showed induction by treatment. A gastric cancer animal model further indicated that the gastric cancer cells significantly promoted tumor growth after treatment . High-throughput miRNA and mRNA sequencing analyses identified a subset of miRNAs and mRNAs under regulation of both 5-Fu and in gastric cancer cells, including upregulation of and downregulation of . Targeted overexpression or knockdown of in gastric cancer cells revealed the oncogenic function of in regulating gastric cancer by suppressing target gene signaling pathway, as a downstream target of , showed activation and after treatment with or . Our findings not only revealed a novel mechanism through which chemotherapy induced CSCs in gastric cancer via signaling, but also provided an experimental evidence for appropriate dose reduction of adjuvant chemotherapy in treatment of cancer patients.

Citing Articles

Advanced progress in the genetic modification of the oncolytic HSV-1 virus.

Zhou M, Shen Z Front Oncol. 2025; 14:1525940.

PMID: 39906660 PMC: 11790444. DOI: 10.3389/fonc.2024.1525940.

KHSRP promotes cancer stem cell maintenance, tumorigenesis, and suppresses anti-tumor immunity in gastric cancer.

Du Y, Pei Z, Hu S, Liao C, Liu S Oncol Res. 2025; 33(2):309-325.

PMID: 39866240 PMC: 11753988. DOI: 10.32604/or.2024.058273.

Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer.

Chen M, Wang T, Tian D, Hai C, Qiu Z Heliyon. 2024; 10(18):e37263.

PMID: 39309860 PMC: 11416542. DOI: 10.1016/j.heliyon.2024.e37263.

Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting.

Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W Genes Dis. 2024; 11(3):101043.

PMID: 38292177 PMC: 10825311. DOI: 10.1016/j.gendis.2023.05.024.

Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment.

Moreno-Londono A, Robles-Flores M Stem Cell Rev Rep. 2023; 20(1):25-51.

PMID: 37922108 PMC: 10799829. DOI: 10.1007/s12015-023-10647-6.

References

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

Pan Y, Shu X, Sun L, Yu L, Sun L, Yang Z . miR‑196a‑5p modulates gastric cancer stem cell characteristics by targeting Smad4. Int J Oncol. 2017; 50(6):1965-1976. PMC: 5435324. DOI: 10.3892/ijo.2017.3965. View

Gutschalk C, Herold-Mende C, Fusenig N, Mueller M . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006; 66(16):8026-36. DOI: 10.1158/0008-5472.CAN-06-0158. View

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

Seo S, Ryu M, Park Y, Ahn J, Park Y, Park S . Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2018; 22(3):527-535. DOI: 10.1007/s10120-018-0891-1. View

Uemura Y, Kobayashi M, Nakata H, Harada R, Kubota T, Taguchi H . Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. Int J Cancer. 2004; 109(6):826-32. DOI: 10.1002/ijc.20023. View

Xu Z, Tang J, Xie H, Du Y, Huang L, Yu P . 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015; 11(3):284-94. PMC: 4323368. DOI: 10.7150/ijbs.10248. View

Benna M, Guy J, Bosacki C, Jmour O, Ben Mrad M, Ogorodniitchouk O . Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?. Br J Radiol. 2020; 93(1109):20190147. PMC: 7217575. DOI: 10.1259/bjr.20190147. View

Sun X, Jiao X, Pestell T, Fan C, Qin S, Mirabelli E . MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 2013; 33(42):4967-77. DOI: 10.1038/onc.2013.492. View

10.

Metcalf D . The colony-stimulating factors and cancer. Nat Rev Cancer. 2010; 10(6):425-34. PMC: 3345291. DOI: 10.1038/nrc2843. View

11.

Gomes B, Rueff J, Rodrigues A . MicroRNAs and Cancer Drug Resistance. Methods Mol Biol. 2016; 1395:137-62. DOI: 10.1007/978-1-4939-3347-1_9. View

12.

Lu J, Wang Y, Yoon C, Huang X, Xu Y, Xie J . Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2019; 471:38-48. DOI: 10.1016/j.canlet.2019.11.038. View

13.

Hong I . Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med. 2016; 48(7):e242. PMC: 4973317. DOI: 10.1038/emm.2016.64. View

14.

Takaishi S, Okumura T, Tu S, Wang S, Shibata W, Vigneshwaran R . Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009; 27(5):1006-20. PMC: 2746367. DOI: 10.1002/stem.30. View

15.

Ju H, Xing W, Yang J, Zheng Y, Jia X, Zhang B . An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model. BMC Immunol. 2016; 17(1):31. PMC: 5037582. DOI: 10.1186/s12865-016-0172-x. View

16.

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B . Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. J Hematol Oncol. 2015; 8:16. PMC: 4345016. DOI: 10.1186/s13045-015-0113-9. View

17.

Carlson S, Chouinard C, Labadorf A, Lam C, Schmelzle K, Fraenkel E . Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3. Sci Signal. 2011; 4(196):rs11. PMC: 3779841. DOI: 10.1126/scisignal.2002010. View

18.

Guo W, Li W, Yuan L, Mei X, Hu W . MicroRNA-106a-3p Induces Apatinib Resistance and Activates Janus-Activated Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. Med Sci Monit. 2019; 25:10122-10128. PMC: 6948289. DOI: 10.12659/MSM.919610. View

19.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

20.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View